Differences in vanadocene dichloride and cisplatin effect on MOLT-4 leukemia and human peripheral blood mononuclear cells.

Abstract

Modern chemotherapy is interested in developing new agents with high efficiency of treatment in low-dose medication strategies, lower side toxicity and stronger specificity to the tumor cells. Vanadocene dichloride (VDC) belongs to the group of the most promising metallocene antitumor agents; however, its mechanism of action and cytotoxicity profile are not fully understood. In this paper we assess cytotoxic effects of VDC in comparison to cisplatin using opposite prototype of cells; human peripheral blood mononuclear (PBMCs) cells and human acute lymphoblastic leukemia cell line (MOLT-4). Our findings showed cytotoxic effect of VDC on leukemia cells, but unfortunately on human peripheral blood mononuclear cells as well. VDC induces apoptosis in leukemia cells; the induction is, however, lower than that of cisplatin, and in contrary to cisplatin, VDC does not induce p53 up-regulation. Cytotoxic effect of VDC on leukemia cells is less pronounced than that of cisplatin and more pronounced in PBMCs than in MOLT-4 cells.

• Authors: Radim Havelek, Pavel Siman, Jana Cmielova, Alena Stoklasova, Jirina Vavrova, Jaromir Vinklarek, Jiri Knizek, Martina Rezacova
• Journal: Medicinal chemistry (Shariqah (United Arab Emirates)) (Med Chem) Vol. 8 Issue 4 Pg. 615-21 (Jul 2012) ISSN: 1875-6638 [Electronic] Netherlands
• PMID: 22530915 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Vanadium Compounds
• vanadocene dichloride
• Cisplatin

Topics

• Cell Cycle (drug effects)
• Cell Line
• Cell Survival (drug effects)
• Cisplatin (pharmacology)
• Flow Cytometry
• Humans
• Leukemia (drug therapy)
• Leukocytes, Mononuclear (drug effects)
• Vanadium Compounds (pharmacology)